Patents by Inventor Yongke Zhang

Yongke Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140322239
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: APEXIGEN, INC.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • Patent number: 8778345
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: July 15, 2014
    Assignee: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Patent number: 8753634
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: June 17, 2014
    Assignee: Apexigen, Inc.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • Publication number: 20140120103
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: October 30, 2013
    Publication date: May 1, 2014
    Applicant: Apexigen, Inc.
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20130330355
    Abstract: The present invention provides anti-IL-1? monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of inflammatory and other diseases.
    Type: Application
    Filed: September 9, 2011
    Publication date: December 12, 2013
    Applicant: APEXIGEN, INC.
    Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang
  • Publication number: 20130089540
    Abstract: The present invention discloses methods of design and preparation for a new humanized anti-CD20 monoclonal antibody, related genes, protein sequence, and the use of said antibody. Comparing to murine-derived antibodies and human-mouse chimeric antibodies, said humanized anti-CD20 antibody maintains or improves high binding activity of the variable regions, meanwhile reduces the immunogenicity of chimeric antibodies, consequently achieves the effect of reducing medicine side effects and improving clinical treatment. The antibody disclosed by the present invention is efficiently expressed in animal cells, can be used for industrial production. It could be used in treating B cell lymphoma, leukaemia, or B cell-associated autoimmune disease with a wide application prospect.
    Type: Application
    Filed: March 16, 2011
    Publication date: April 11, 2013
    Applicant: BIOEX THERAPEUTICS, INC.
    Inventors: Jie Liu, Yongke Zhang
  • Publication number: 20120301488
    Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
    Type: Application
    Filed: April 27, 2012
    Publication date: November 29, 2012
    Inventors: Yongke Zhang, Guo-Liang Yu, Weimin Zhu
  • Publication number: 20120231011
    Abstract: The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.
    Type: Application
    Filed: August 27, 2010
    Publication date: September 13, 2012
    Applicants: Apexigen Inc., Jiangsu Simcere Pharmaceutical R&D Co., Ltd
    Inventors: Pierre Li, Yaohuang ke, Yongke Zhang, Weimin Zhu, Guoliang Yu, Fanxin Ma, Xin Fan
  • Publication number: 20120225060
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: February 28, 2012
    Publication date: September 6, 2012
    Applicant: APEXIGEN, INC.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • Publication number: 20080260740
    Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
    Type: Application
    Filed: June 12, 2008
    Publication date: October 23, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Yongke ZHANG, Vanitha RAMAKRISHNAN, Debbie LAW
  • Patent number: 7399469
    Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: July 15, 2008
    Assignee: PDL BioPharma, Inc.
    Inventors: Yongke Zhang, Vanitha Ramakrishnan, Debbie Law
  • Publication number: 20050260212
    Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
    Type: Application
    Filed: March 25, 2005
    Publication date: November 24, 2005
    Inventors: Yongke Zhang, Vanitha Ramakrishnan, Debbie Law